Pharmaceuticals, Biotechnology and Life Sciences
CAMBRIDGE, Mass.–(BUSINESS WIRE)–AVEO Oncology (NASDAQ: AVEO) today announced that it has initiated enrollment in an open-label, multi-center Phase 1b/2 clinical…
– 22% Response Rate; 61% Disease Control Observed – REHOVOT, Israel & WILMINGTON, Del.–(BUSINESS WIRE)–Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical…
– First Presentation of Tucatinib With Trastuzumab in Metastatic Colorectal Cancer – – Findings Presented Today at the European Society…
– Phase I dose escalation continues; dosing is within the therapeutic range predicted by preclinical models – Early analysis of…
$46 Million Series A Round Co-led by ARCH Venture Partners and City Hill Ventures Company is Developing a Novel Class…
— The Company’s GPR174 Inhibitors Enhance Anti-Tumor Activities of Adenosine Pathway Inhibitors by up to 25-Fold — SEATTLE–(BUSINESS WIRE)–Omeros Corporation…
DUBLIN–(BUSINESS WIRE)–The “Opdivo” drug pipelines has been added to ResearchAndMarkets.com’s offering. Opdivo (nivolumab; Bristol-Myers Squibb/Ono Pharmaceutical) is a fully human…
The combination did not demonstrate statistical significance in outperforming the single agents in the overall population
Cutting Edge Platform Enables the Detection of Changes in the Tumor Microenvironment Following Treatment with FLX475 MENLO PARK, Calif. &…
DUBLIN–(BUSINESS WIRE)–The “Global Chemotherapy Drugs Market: Analysis By Drug Type (Antimetabolites, Plant Alkaloids, Alkylating Agents, Antitumor Antibiotics), By Administration (Oral,…